Murray Aitken

1.3k total citations
23 papers, 822 citations indexed

About

Murray Aitken is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Pharmacology. According to data from OpenAlex, Murray Aitken has authored 23 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 6 papers in Public Health, Environmental and Occupational Health and 6 papers in Pharmacology. Recurrent topics in Murray Aitken's work include Pharmaceutical Economics and Policy (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical industry and healthcare (5 papers). Murray Aitken is often cited by papers focused on Pharmaceutical Economics and Policy (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Pharmaceutical industry and healthcare (5 papers). Murray Aitken collaborates with scholars based in United States, United Kingdom and Switzerland. Murray Aitken's co-authors include Ernst R. Berndt, Brian Francis, John Hinde, Daniel C. Coster, Dorothy A. Anderson, David Cutler, P. A. Lachenbruch, John Hinds, Dorothy Anderson and Charlotte Johnston-Webber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American Statistical Association and Nature Reviews Drug Discovery.

In The Last Decade

Murray Aitken

21 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Murray Aitken United States	13	291	119	89	84	79	23	822
Anke Richter United States	15	190 0.7×	100 0.8×	66 0.7×	13 0.2×	92 1.2×	45	1.1k
Bennett Levitan United States	20	530 1.8×	94 0.8×	11 0.1×	119 1.4×	73 0.9×	80	1.3k
Mark Barnes United States	14	135 0.5×	368 3.1×	12 0.1×	89 1.1×	28 0.4×	70	851
Michael P. Douglas United States	23	301 1.0×	229 1.9×	6 0.1×	120 1.4×	179 2.3×	61	2.0k
Megan C. Roberts United States	20	221 0.8×	287 2.4×	13 0.1×	31 0.4×	132 1.7×	96	1.4k
Nigel Hawkes United States	12	192 0.7×	187 1.6×	13 0.1×	42 0.5×	77 1.0×	407	1.2k
Maximilian Salcher‐Konrad United Kingdom	11	302 1.0×	91 0.8×	8 0.1×	15 0.2×	50 0.6×	29	1.3k
Alexander Finlayson United Kingdom	21	177 0.6×	191 1.6×	47 0.5×	57 0.7×	70 0.9×	52	1.1k
Driss Oraichi Canada	14	100 0.3×	470 3.9×	39 0.4×	21 0.3×	197 2.5×	26	1.2k
Rebecca J. Williams United States	8	367 1.3×	495 4.2×	9 0.1×	107 1.3×	57 0.7×	17	1.2k

Countries citing papers authored by Murray Aitken

Since Specialization

Citations

This map shows the geographic impact of Murray Aitken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Aitken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Aitken more than expected).

Fields of papers citing papers by Murray Aitken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray Aitken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Aitken. The network helps show where Murray Aitken may publish in the future.

Co-authorship network of co-authors of Murray Aitken

This figure shows the co-authorship network connecting the top 25 collaborators of Murray Aitken. A scholar is included among the top collaborators of Murray Aitken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray Aitken. Murray Aitken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oo, Myo Minn, Sahan Jayawardana, Allen Campbell, et al.. (2025). Trends in global glucose lowering medication consumption: Insights from pharmaceutical sales data (2010–2021). PLOS Global Public Health. 5(10). e0005326–e0005326.

Jayawardana, Sahan, Allen Campbell, Murray Aitken, et al.. (2024). Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010–2021. SHILAP Revista de lepidopterología. 4(9). e0003698–e0003698. 1 indexed citations

Leufkens, Hubert G. M., Murray Aitken, Jarno Hoekman, et al.. (2022). Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today. 27(8). 2252–2260. 6 indexed citations

Jayawardana, Sahan, Rebecca Forman, Charlotte Johnston-Webber, et al.. (2021). Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. EClinicalMedicine. 42. 101198–101198. 80 indexed citations

Cameron, David, et al.. (2020). Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. Clinical Therapeutics. 42(8). e150–e159. 15 indexed citations

Westrich, Kimberly, et al.. (2019). Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?. Value in Health. 22(7). 792–798.

Danhof, Meindert, Kevin Klein, Pieter Stolk, Murray Aitken, & Hubert G. M. Leufkens. (2018). The future of drug development: the paradigm shift towards systems therapeutics. Drug Discovery Today. 23(12). 1990–1995. 24 indexed citations

Wolff‐Holz, Elena, Rosa Giuliani, Johan De Munter, et al.. (2018). Preparing for the incoming wave of biosimilars in oncology. ESMO Open. 3(6). e000420–e000420. 7 indexed citations

Aitken, Murray, et al.. (2016). Has The Era Of Slow Growth For Prescription Drug Spending Ended?. Health Affairs. 35(9). 1595–1603. 29 indexed citations

10.

Aitken, Murray. (2016). Understanding the pharmaceutical value chain. Pharmaceuticals Policy and Law. 18(1-4). 55–66. 26 indexed citations

11.

Berndt, Ernst R., et al.. (2015). Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations. Health Affairs. 34(2). 245–252. 54 indexed citations

12.

Aitken, Murray, et al.. (2013). Defining and quantifying the use of personalized medicines. Nature Reviews Drug Discovery. 12(12). 896–897. 7 indexed citations

13.

Berndt, Ernst R. & Murray Aitken. (2011). Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation. International Journal of the Economics of Business. 18(2). 177–201. 58 indexed citations

14.

Berndt, Ernst R. & Murray Aitken. (2010). Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation. SSRN Electronic Journal. 3 indexed citations

15.

Trusheim, Mark, Murray Aitken, & Ernst R. Berndt. (2010). Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. Forum for Health Economics & Policy. 13(1). 14 indexed citations

16.

Trusheim, Mark, Murray Aitken, & Ernst R. Berndt. (2010). Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. SSRN Electronic Journal. 2 indexed citations

17.

Aitken, Murray, Ernst R. Berndt, & David Cutler. (2008). Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point. Health Affairs. 27(Suppl1). w151–w160. 99 indexed citations

18.

Aitken, Murray, et al.. (2000). A Prescription for Direct Drug Marketing. The McKinsey Quarterly. 82. 8 indexed citations

19.

Aitken, Murray, et al.. (2000). A License to Cure. The McKinsey Quarterly. 80. 5 indexed citations

20.

Lachenbruch, P. A., Murray Aitken, Dorothy Anderson, Brian Francis, & John Hinds. (1990). Statistical Modelling in GLIM.. Journal of the American Statistical Association. 85(409). 267–267. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact